Cas9 Stable Cell Line - ISHIKAWA

The ISHIKAWA cell line is a mature human endometrial adenocarcinoma cell line derived from endometrial cancer patients. Due to its epithelial origin, hormone sensitivity, and relevance to gynecological cancers, this cell line is widely used in oncology and molecular biology research. The Cas9 Stable Cell Line - ISHIKAWA is a genetically engineered variant in which CRISPR-associated protein 9 (Cas9) is stably integrated into the genome. This modification allows for stable and efficient gene editing without transient transfection, ensuring continuous expression of Cas9 during cell passage.

The Cas9 Stable Cell Line - ISHIKAWA is a powerful tool for functional genomics and cancer research. Researchers use it to study gene function in the pathogenesis of endometrial cancer through targeted knockout or mutation, such as tumor suppressor genes (e.g., PTEN) or oncogenes (e.g., PIK3CA). It facilitates high-throughput CRISPR screening to identify novel therapeutic targets or drug resistance mechanisms in hormone-driven cancers. Furthermore, this cell line is well-suited for studying estrogen and progesterone signaling pathways, providing insights into hormone receptor interactions and drug responses. Beyond oncology, it supports research on DNA repair mechanisms, apoptosis regulation, and metastasis. Its stable Cas9 expression simplifies workflows, reduces experimental variability and costs associated with repeated transfections, thereby accelerating drug discovery and personalized medicine.